Industry preview: Eye care companies announce presentations ahead of ASRS meeting

As the ASRS meeting draws near, industry leaders announce presentations related to their research. Image credit: ©as-artmedia – stock.adobe.com

The retina community is busy as they prepare for one of its biggest events of the year, the American Society of Retina Specialists (ASRS) annual meeting. The 42nd ASRS Annual Scientific Meeting will be held 17-20 July in Stockholm, Sweden.

This meeting will connect retina specialists from around the country and the globe to discuss the latest research, discuss clinical trials and network with one another. Companies also use this event to showcase new data and update the community on the progress of pharmaceutical candidates, as well as surgical techniques and practice management techniques.

As the meeting draws nearer, more companies have announced presentations related to their research. Below is a non-exhaustive list of companies and the information surrounding their ASRS presentations (in alphabetical order).

The Eye Care Network will continue to highlight additional announcements as they are made.

Annexon Inc.

The company will have two oral presentations at the ASRS meeting. The first, by Glenn J. Jaffe, MD, entitled, "Protective Effects of ANX007 on Central Macular Ellipsoid Zone (EZ) and Retinal Pigment Epithelium (RPE) and Association with Visual Acuity in the Phase 2 ARCHER GA Study" will take place on 18 July, at 8:42 am CEST.¹

The second will be presented by Joel Pearlman, MD, PhD, and will be, "Preservation of Vision by ANX007: Clinical Results and Anatomic Changes From the Phase 2 ARCHER Trial." This presentation will take place on 18 July at 1:36 pm CEST.¹

Apellis Pharmaceuticals

Apellis has announced that data on the efficacy and safety of pegcetacoplan will be featured in several presentations at the ASRS meeting along with studies on geographic atrophy.² These will include:

• Pegcetacoplan vs Avacincaptad Pegol in Geographic Atrophy: Anchored Matching-Adjusted Indirect Comparisons of Three Phase 3 Trials Over 24 Months
  • Presenter: Paul Hahn, MD, PhD, FASRS
  • Wednesday, 17 July, 9:30 am CEST
• Identification of Disease Activity and Therapeutic Response in Geographic Atrophy by Human Experts and OCT-Based AI Analysis in Pegcetacoplan Therapy
  • Presenter: Ursula M Schmidt-Erfurth, MD
  • Wednesday, 17 July, 11:00 am CEST
• Predictive Role of Outer Retinal Tubulation in Lesion Growth for Subfoveal and Nonsubfoveal Geographic Atrophy
  • Presenter: Srinivas Sai A Kondapalli, MD
  • Thursday, 18 July, 8:34 am CEST
• Update on Pegcetacoplan for Geographic Atrophy: Clinical Studies and Real-World Experience
  • Presenter: David A Eichenbaum, MD, FASRS
  • Thursday, 18 July, 3:25 pm CEST
• Visual Function Benefit of Pegcetacoplan on a Prespecified Microperimetry Endpoint after 36 Months of Continuous Treatment from GALE
  • Presenter: Sunir J Garg, MD, FACS, FASRS
  • Thursday, 18 July, 3:25 pm CEST

Nanoscope Therapeutics

A presentation, titled, “BCVA analysis of low- or high-dose MCO-010 mutation agnostic optogenetic therapy for retinitis pigmentosa: FIRST TIME 100-week TOPLINE Results from a Phase 2b/3 Randomised Sham-Controlled Clinical Trial (RESTORE)” will be given by Michael Singer, MD on Friday, 19 July, at 9:17 am CEST. This will cover the recently announced 100-week data from on the candidate MCO-010.³

Ocular Therapeutix

Ocular Therapeutix announced a late-breaking abstract on their HELIOS Phase 1 study will be presented by Dilsher S. Dhoot, MD. The presentation entitled, Interim Safety and Efficacy Results From the Phase 1 HELIOS Trial of Sustained-release Axitinib Implant (OTX-TKI) for NPDR,” will take place on 18 July, 2024 at 10:47 am CEST.⁴

Ocuphire Pharma

The company will share a virtual paper-on-demand as part of the ASRS meeting. This presentation, given by Kareem Sioufi, MD, entitled “Effect of Oral APX3330 on Progression of Non-Proliferative Diabetic Retinopathy Utilising a Binocular DRSS Person-Level Scale,” will be available to ASRS attendees beginning 17 July, 2024 in the on-demand content library.⁵

References:

1. Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting. Published July 11, 2024. Accessed July 12, 2024. https://www.globenewswire.com/news-release/2024/07/11/2912176/0/en/Annexon-to-Present-Additional-Phase-2-Data-Showing-Preservation-of-Visual-Function-and-Structure-by-ANX007-in-Geographic-Atrophy-at-the-42nd-ASRS-Annual-Scientific-Meeting.html

2. Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting. Apellis Pharmaceuticals, Inc. Published July 9, 2024. Accessed July 11, 2024. https://www.globenewswire.com/news-release/2024/07/09/2910191/0/en/Apellis-Announces-Five-Abstracts-Accepted-for-Oral-Presentation-at-the-American-Society-of-Retina-Specialists-ASRS-Annual-Scientific-Meeting.html

3. Nanoscope Therapeutics to Present at the 2024 American Society of Retina Specialists (ASRS) Annual Scientific Meeting. Nanoscope Therapeutics. Published July 10, 2024. Accessed July 11, 2024. https://www.prnewswire.com/news-releases/nanoscope-therapeutics-to-present-at-the-2024-american-society-of-retina-specialists-asrs-annual-scientific-meeting-302192579.html

4. Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting. Ocular Therapeutix. Published July 10, 2024. Accessed July 10, 2024. https://www.globenewswire.com/news-release/2024/07/10/2911060/0/en/Ocular-Therapeutix-Announces-Late-Breaking-Abstract-of-HELIOS-Study-to-be-Presented-at-42nd-ASRS-Annual-Scientific-Meeting.html#

5. Ocuphire Pharma to Highlight APX3330 for Diabetic Retinopathy at Two Scientific Meetings in July. Ocuphire Pharma. Published July 10, 2024. Accessed July 11, 2024. https://www.biospace.com/article/releases/ocuphire-pharma-to-highlight-apx3330-for-diabetic-retinopathy-at-two-scientific-meetings-in-july/